Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination DAAs for HCV Genotype 1b (SODAPI II)
NCT02932293Phase 2Withdrawn
- Sponsor
- Humanity & Health Research Centre
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of simeprevir, sofosbuvir, daclatasvir in hepatitis C (HCV), sponsored by Humanity & Health Research Centre. Planned start Dec 2016; status: withdrawn.
02
Drugs
simeprevirsofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02932293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932293.